ALNY Shariah Compliance
Screening Methodology: AAOIFI
LOCKED
Alnylam Pharmaceuticals Inc. Stock Analysis ALNY
United States Health Care Large Cap Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 2,230 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.
Read More ALNY Chart
Alnylam Pharmaceuticals Inc vs S&P 500 Comparative Returns
Analysis of ALNY stock performance compared to the broader market (S&P 500) across multiple timeframes.
YTD Performance
- Alnylam Pharmac... (ALN...) 78.02%
- S&P 500 8.2%
Alnylam Pharmac... Outperformed S&P 500 by 69.82%
1Y Performance
- Alnylam Pharmac... (ALN...) 58.08%
- S&P 500 17.63%
Alnylam Pharmac... Outperformed S&P 500 by 40.45%
3Y Performance
- Alnylam Pharmac... (ALN...) 91.65%
- S&P 500 54.54%
Alnylam Pharmac... Outperformed S&P 500 by 37.11%
5Y Performance
- Alnylam Pharmac... (ALN...) 190.67%
- S&P 500 94.73%
Alnylam Pharmac... Outperformed S&P 500 by 95.94%
Key Statistics of Alnylam Pharmaceuticals Inc(ALNY)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$429.33Volume
1.18MP/E Ratio (TTM)
-52 Week Range
Market Cap
42.41BAvg. Volume
1.16MDividend Yield
-Financial Metrics & Statements of Alnylam Pharmaceuticals Inc(ALNY)
- Per Share Data
- Ratios
- Statements
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Revenue per Share (TTM) | 4.23 | 7.02 | 8.37 | 14.53 | - |
EBIT per Share (TTM) | -7.12 | -5.9 | -6.34 | -2.24 | - |
Earnings per Share (EPS) (TTM) | - | -7.2 | -9 | -3 | - |
EPS Forward | - | - | - | -3.52 | -2.18 |
Annual 
Quarterly
| Currency: USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Net Margin | -1.74 | -1.01 | -1.09 | -0.24 | -0.12 |
Quick Ratio | 4.23 | 3.79 | 3.16 | 2.86 | 2.61 |
Current Ratio | 4.47 | 4.04 | 3.51 | 3.08 | 2.78 |
Price to Earnings (TTM) | 0 | 0 | 0 | 0 | 0 |
price_to_earning | 0 | 0 | 0 | 0 | 0 |
Price to Sales (TTM) | 0 | 0 | 0 | 0 | 0 |
Price to Book | 14.86 | 34.48 | 0 | 0 | 452.4 |
Free Cash Flow Margin | 0 | 0 | 0 | 0.02 | 0 |
Payout Ratio (TTM) | 0 | 0 | 0 | 0 | 0 |
Gross Margin | 0.84 | 0.83 | 0.84 | 0.83 | 0.86 |
Return on Equity (TTM) | 0 | 0 | 0 | 0 | 0 |
Return on Assets | -0.25 | -0.23 | -0.32 | -0.11 | -0.07 |
Return on Assets (TTM) | 0 | 0 | 0 | 0 | 0 |
Return on Invested Capital | -0.71 | -0.67 | 0 | 0 | -0.25 |
Inventory Turnover (TTM) | 0 | 0 | 0 | 0 | 0 |
Receivables Turnover (TTM) | 0 | 0 | 0 | 0 | 0 |
Asset Turnover (TTM) | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt to Equity | 0.19 | 1.15 | 0 | 0 | 15.27 |
Total Debt to Total Asset | 0.06 | 0.19 | 0.29 | 0.27 | 0.24 |
Long-Term Debt to Total Asset | 0.06 | 0.19 | 0.29 | 0.27 | 0.24 |
Total Debt to Total Capital | 0.16 | 0.53 | 1.18 | 1.28 | 0.94 |
Operating Margin | -1.68 | -0.84 | -0.83 | -0.15 | -0.08 |
Price to Earning | - | -23.55 | -26.41 | -63.8 | - |
Super Investors
Super Investors are top-performing investors known for their exceptional market strategies and long-term success in wealth creation.
Dodge & Cox
% Portfolio:
0.52 Recent Activity:-5.32%
George Soros
% Portfolio:
0.29 Recent Activity:100.00%
Jefferies Group
% Portfolio:
0.07 Recent Activity:100.00%
Joel Greenblatt
% Portfolio:
0.03 Recent Activity:32.89%
Community-Curated Collections ( With ALNY )
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
FAQ's
Halal stocks refer to shares of companies that comply with Islamic finance principles, meaning they do not engage in businesses related to alcohol, gambling, pork, or interest-based financial services.
Alternate Halal Stocks
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
